Who are Brimonidine/Timolol mixed combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combigan Two Times Daily (BID), treatment with brimonidine/timolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brimonidine-timolol-mixed-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Brimonidine/Timolol mixed combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brimonidine/Timolol mixed combination (Brimonidine/Timolol mixed combination) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist / Beta-blocker combination. Area: Ophthalmology.

marketed Alpha-2 adrenergic agonist / Beta-blocker combination Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine/Timolol mixed combination (Brimonidine/Timolol mixed combination) — Seoul National University Hospital. Brimonidine is an alpha-2 adrenergic agonist and timolol is a non-selective beta-blocker; together they reduce intraocular pressure through different pathways.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brimonidine/Timolol mixed combination TARGET	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Combigan Two Times Daily (BID)	Combigan Two Times Daily (BID)	Cornerstone Health Care, PA	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker	Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist / Beta-blocker combination class)

Aristotle University Of Thessaloniki · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine/Timolol mixed combination — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-timolol-mixed-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab